Last updated: September 2, 2026
Duvelisib, marketed as Copiktra, is an oral PI3K-delta/gamma inhibitor developed for heavily pretreated chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma. The product achieved FDA approval in 2018 but developed a limited commercial profile because of safety warnings, competition from BTK and BCL2 inhibitors, restricted use in later-line disease and the withdrawal of its U.S. commercial product.
The key financial event was Verastem’s 2019 sale of U.S. commercial rights to Secura Bio for $70 million upfront, with potential milestone payments. Duvelisib generated meaningful but modest revenue relative to competing hematology products. Its commercial value declined as the PI3K inhibitor class faced safety-related regulatory pressure and as physicians shifted toward newer targeted therapies.
What is duvelisib and which cancers does Copiktra treat?
Duvelisib is a selective oral inhibitor of phosphoinositide 3-kinase delta and gamma. PI3K-delta is important in B-cell signaling, while PI3K-gamma affects immune-cell signaling and the tumor microenvironment.
The FDA approved Copiktra on Sept. 24, 2018, for:
| Disease |
FDA-approved use |
| CLL or SLL |
Adult patients with relapsed or refractory disease after at least two prior systemic therapies |
| Follicular lymphoma |
Adult patients with relapsed or refractory disease after at least two prior systemic therapies |
The follicular lymphoma approval was granted under the accelerated approval pathway. The CLL/SLL approval was based primarily on the DUO study, a randomized Phase 3 trial comparing duvelisib with ofatumumab. Duvelisib improved progression-free survival in the study population, but its risk-benefit profile remained difficult to position against better-established targeted therapies (U.S. Food and Drug Administration, 2018a).
Copiktra carries boxed warnings for fatal and serious infections, diarrhea or colitis, cutaneous reactions and pneumonitis. The label also includes warnings for hepatotoxicity, neutropenia and embryo-fetal toxicity.
How large was the addressable market for duvelisib?
Duvelisib entered a large hematologic oncology market but occupied a narrow segment of it. Its principal addressable populations were patients with relapsed or refractory B-cell malignancies who had already received multiple treatments.
The commercial opportunity was constrained by four factors:
- Most eligible patients were already exposed to highly effective targeted therapies.
- Treatment guidelines increasingly favored BTK inhibitors, venetoclax-based regimens and, later, noncovalent BTK inhibitors.
- PI3K inhibitors developed a class-wide reputation for immune-mediated toxicity and infectious complications.
- The label required treatment in heavily pretreated patients rather than in a broad first-line population.
The drug therefore competed for a later-line niche instead of the high-volume front-line CLL or follicular lymphoma markets.
How does duvelisib compare with competing hematology drugs?
| Product |
Target or mechanism |
Main commercial advantage over duvelisib |
| Imbruvica, ibrutinib |
BTK inhibitor |
Earlier-line use, established physician familiarity and broad CLL positioning |
| Calquence, acalabrutinib |
BTK inhibitor |
Strong CLL positioning with a differentiated tolerability profile |
| Brukinsa, zanubrutinib |
BTK inhibitor |
Increasing use in B-cell malignancies and competitive efficacy |
| Venclexta, venetoclax |
BCL2 inhibitor |
Fixed-duration treatment strategies and deep responses |
| Jaypirca, pirtobrutinib |
Noncovalent BTK inhibitor |
Activity after covalent BTK inhibitor exposure |
| Zydelig, idelalisib |
PI3K-delta inhibitor |
Earlier entry in the PI3K category, but similar class-level safety concerns |
| Copiktra, duvelisib |
PI3K-delta/gamma inhibitor |
Dual delta/gamma mechanism and oral administration |
Duvelisib’s dual PI3K-delta/gamma activity was scientifically differentiated, but the differentiation did not translate into a strong commercial advantage. Efficacy had to be weighed against infection risk, immune-mediated adverse events and the availability of alternatives.
What was duvelisib’s financial trajectory?
Verastem launched Copiktra in the United States in late 2018 and transferred U.S. commercial rights to Secura Bio in late 2019. Verastem retained economic participation through the transaction but stopped reporting Copiktra as a conventional directly commercialized product.
The public financial record indicates a short period of direct product revenue followed by a transition to licensing and royalty economics.
| Period |
Financial development |
Commercial interpretation |
| 2018 |
U.S. launch after FDA approval |
Initial sales were limited by the late-year launch |
| 2019 |
Early commercial expansion; Verastem agreed to transfer U.S. rights |
Product required greater commercialization scale and oncology-channel execution |
| 2020 |
Secura Bio assumed commercial responsibility |
Verastem’s economics shifted from direct product sales toward licensing-related revenue and royalties |
| 2021-2022 |
Duvelisib remained a niche hematology product |
Competition and safety concerns limited growth |
| 2023-2024 |
U.S. commercial withdrawal process |
Revenue opportunity contracted materially and future U.S. sales became non-core |
Verastem’s 2019 agreement with Secura Bio included a $70 million upfront payment and potential additional milestone payments. The transaction reduced Verastem’s commercial infrastructure requirements and provided non-dilutive capital for its oncology pipeline (Verastem Oncology, 2019).
Reported revenue figures must be read in the context of this transfer. Verastem’s post-2019 filings do not provide a simple, uninterrupted series of Copiktra net product sales comparable with a fully integrated pharmaceutical company. Secura Bio is privately held and has not provided the same level of product-specific revenue disclosure as a public issuer.
What drove the decline in duvelisib’s financial outlook?
The principal factors were:
- Later-line label positioning.
- High monitoring and adverse-event management requirements.
- Physician migration toward BTK and BCL2 regimens.
- Negative safety perception affecting the broader PI3K inhibitor class.
- Difficulty converting accelerated approval into a durable commercial franchise.
- U.S. withdrawal of the commercial product.
The product’s economic value was therefore front-loaded around the approval, rights transaction and potential royalty stream rather than sustained blockbuster sales.
When did duvelisib lose exclusivity?
Duvelisib’s FDA regulatory exclusivity and patent protection have different timelines.
The product received five-year new chemical entity exclusivity from the 2018 approval date. That period expired in September 2023. The CLL/SLL indication also received orphan-drug exclusivity, generally extending seven years from approval for the qualifying indication, subject to the scope of the orphan designation and applicable FDA rules.
| Protection type |
Approximate end date |
Commercial effect |
| New chemical entity exclusivity |
Sept. 24, 2023 |
ANDA applicants could generally submit after the NCE period ended |
| Orphan-drug exclusivity for the qualifying indication |
Approximately Sept. 24, 2025 |
Could restrict approval of the same drug for the same orphan indication |
| Core patent-family protection |
Nominally extending into the late 2020s and, for certain later patents, early 2030s |
Depends on the specific Orange Book listing, patent claims, PTA/PTE and litigation outcome |
FDA regulatory exclusivity does not automatically prevent all generic activity. A generic applicant may file an ANDA after NCE exclusivity expires, subject to patent certifications and the scope of orphan exclusivity.
What patents protect duvelisib?
Duvelisib is protected by a patent family directed to PI3K inhibitor compounds, pharmaceutical compositions and therapeutic uses. Public patent records identify core U.S. patents including US 8,609,863 and US 8,895,629, along with related continuation and method-of-use patent families.
| Patent category |
Protection focus |
Expected strategic role |
| Composition-of-matter patents |
Duvelisib molecule and related chemical genus |
Primary barrier to generic entry |
| Pharmaceutical composition patents |
Dosage forms and drug compositions |
Secondary protection |
| Method-of-use patents |
Treatment of CLL, SLL, FL and related B-cell disorders |
Potential indication-specific barrier |
| Process and formulation patents |
Manufacturing or dosage-form features |
Usually weaker than composition claims unless difficult to design around |
The most important question for generic entry is whether an Orange Book-listed composition patent remains enforceable and whether a generic applicant can certify that its product does not infringe the listed claims. Method-of-use patents can be relevant where the ANDA label includes a protected indication, although skinny-label strategies may reduce exposure in some circumstances.
How strong is the duvelisib patent estate?
The estate has moderate historical strength but declining commercial leverage.
Its strongest element is the composition-of-matter protection around the active ingredient. That protection is more difficult to design around than a formulation or treatment-method claim. The estate is weaker commercially because:
- The NCE period has expired.
- The product is no longer a broad-growth asset.
- Orphan exclusivity is time-limited and indication-specific.
- Generic manufacturers may target unprotected indications through label carve-outs.
- U.S. commercial withdrawal may reduce the incentive for prolonged patent litigation.
Patent-term adjustment and any patent-term extension affect the exact dates. The FDA Orange Book remains the controlling source for listed patents and expiration information at the product level (U.S. Food and Drug Administration, n.d.-a).
What is the Orange Book status of Copiktra?
Copiktra was approved as a prescription oral capsule. Its Orange Book status is relevant to ANDA filing, patent certification and potential Paragraph IV litigation.
The commercial analysis has three practical points:
- The product’s five-year NCE exclusivity ended in 2023.
- Patent listings, rather than NCE exclusivity, are the principal remaining barrier to a conventional generic challenge.
- A U.S. withdrawal from commercial distribution does not automatically erase FDA approval or eliminate listed patents.
The distinction matters because a product can be commercially withdrawn while remaining approved in FDA databases. Withdrawal also does not necessarily equal a safety-based withdrawal under the Federal Food, Drug, and Cosmetic Act. The legal consequences depend on FDA classification, the withdrawal notice and any subsequent regulatory action.
Which companies are challenging duvelisib, and what is the Paragraph IV risk?
No major public Paragraph IV litigation campaign has established a well-known generic launch date for duvelisib. The absence of a visible challenge does not mean generic entry is impossible. It reflects the product’s relatively small revenue base, remaining patent questions and uncertain commercial return.
Potential ANDA challengers would assess:
- Remaining composition patents.
- Whether orphan exclusivity blocks approval for CLL/SLL or another qualifying indication.
- The commercial value of a skinny-label generic.
- Manufacturing complexity and API supply.
- The cost of patent litigation relative to expected generic sales.
- Whether withdrawal creates a limited market rather than a first-filer opportunity.
A Paragraph IV certification could trigger patent litigation and a 30-month stay under the Hatch-Waxman framework, subject to the statutory conditions and timing of the patent-holder’s response. A first filer could obtain 180-day generic exclusivity, but the value of that exclusivity would be limited if the branded product has little remaining market presence.
What litigation and settlement agreements affect duvelisib?
The most consequential transaction was commercial rather than litigated: Verastem transferred U.S. Copiktra rights to Secura Bio in 2019. The agreement included upfront consideration and potential milestones.
Publicly prominent patent settlements involving duvelisib have not established a clear generic-entry timetable. The absence of a major settlement is consistent with the product’s modest scale and the limited economic value of delayed generic entry.
Safety-related regulatory developments have had greater commercial importance than patent litigation. The FDA label’s boxed warnings and postmarketing risk-management requirements directly affect prescribing, monitoring costs and payer positioning.
What happened to Copiktra’s FDA and commercial status?
Secura Bio announced a voluntary withdrawal of Copiktra from the U.S. market as part of a portfolio and commercial review. The withdrawal materially reduced the product’s U.S. revenue outlook.
The FDA approval history remains important:
- CLL/SLL approval: full approval based on clinical benefit evidence.
- Follicular lymphoma approval: accelerated approval.
- Safety warnings: central to the product’s prescribing profile.
- Commercial withdrawal: separate from automatic revocation of FDA approval.
The follicular lymphoma indication carried a higher regulatory burden because accelerated approval requires confirmatory evidence. A weak or discontinued confirmatory development path can expose the indication to withdrawal, although the exact legal process depends on FDA action and sponsor conduct.
Does duvelisib face biosimilar risk?
Duvelisib has no biosimilar risk because it is a synthetic small-molecule drug, not a biologic. The relevant competitive threat is conventional generic substitution through the ANDA pathway.
The main generic barriers are patent claims, orphan exclusivity, formulation or manufacturing complexity and the economic attractiveness of the market. Biosimilar rules under the Public Health Service Act do not apply to Copiktra.
What generic launch scenarios exist for duvelisib?
Three scenarios define the likely U.S. entry framework.
Scenario 1: Delayed entry after remaining exclusivity
A generic company waits until orphan exclusivity and relevant patents expire. This minimizes litigation risk but sacrifices first-mover advantage.
Scenario 2: Paragraph IV challenge
An ANDA filer challenges one or more patents after NCE exclusivity. The outcome would depend on patent validity, infringement and the scope of any orphan exclusivity. Commercial entry could occur after settlement, litigation victory or patent expiration.
Scenario 3: Skinny-label launch
A generic applicant seeks approval for unprotected indications while carving out protected use language. This strategy could be commercially viable if the remaining market is concentrated in non-protected or non-exclusive uses.
A launch would probably be gradual rather than a high-value patent cliff. The brand’s withdrawal reduces the size of the prize, while generic entry could still be useful for institutional or specialty-pharmacy demand.
How does duvelisib’s market position compare with other PI3K inhibitors?
Duvelisib entered a PI3K market already affected by safety and utilization concerns. Idelalisib had earlier commercial adoption but also faced serious toxicity and label restrictions. Umbralisib, another PI3K inhibitor, was withdrawn after survival concerns in a confirmatory study. These developments damaged confidence in the class and increased scrutiny of risk-management requirements (U.S. Food and Drug Administration, 2022).
Duvelisib’s dual PI3K-delta/gamma profile did not overcome the broader class problem. In practice, hematology treatment decisions increasingly prioritized targeted agents with stronger guideline adoption, more favorable treatment sequencing and, in some cases, fixed-duration regimens.
What geographic markets remain relevant for duvelisib?
The United States was the principal commercial market for Copiktra. Other jurisdictions had smaller and less certain opportunities because approval, reimbursement and commercial availability varied by country.
Geographic value was reduced by:
- Limited use in earlier-line disease.
- Local reimbursement controls.
- Availability of alternative targeted therapies.
- Safety-related physician caution.
- The U.S. withdrawal and reduced sponsor investment.
The remaining value is more likely to reside in selected ex-U.S. markets, specialty access programs or licensing arrangements than in a global expansion strategy.
What manufacturing and intellectual-property barriers affect duvelisib?
Duvelisib is an oral small molecule, so it does not have the cell-line, biologic comparability or cold-chain barriers associated with injectable biologics. Its manufacturing barriers are more conventional:
- Reliable API sourcing.
- Stereochemical and impurity control.
- Reproducible capsule formulation.
- Bioequivalence testing.
- Stability and dissolution performance.
- Compliance with FDA current good manufacturing practice requirements.
These barriers are manageable for experienced generic manufacturers. They are unlikely to protect the product indefinitely once composition patents and regulatory exclusivity expire.
Key Takeaways
- Duvelisib received FDA approval in 2018 for heavily pretreated CLL/SLL and follicular lymphoma.
- Its market was constrained by later-line use, serious safety warnings and competition from BTK and BCL2 inhibitors.
- Verastem transferred U.S. commercial rights to Secura Bio in 2019 for $70 million upfront plus potential milestones.
- The product’s financial trajectory shifted from direct sales to licensing and royalty economics after the transaction.
- Five-year NCE exclusivity expired in September 2023.
- Orphan exclusivity for the qualifying indication was expected to run approximately through September 2025.
- Composition patents and related patent families extend nominal protection into the late 2020s or early 2030s, depending on the specific listing and term adjustment.
- Duvelisib has generic risk, not biosimilar risk.
- No major public Paragraph IV settlement has established a clear generic launch date.
- U.S. commercial withdrawal materially reduced the product’s future revenue potential.
FAQs About Duvelisib Commercial and Patent Risk
Is duvelisib still FDA approved?
Commercial withdrawal does not automatically terminate FDA approval. Copiktra’s marketing status must be distinguished from its availability through the sponsor and from any separate FDA withdrawal action.
What was the peak commercial opportunity for Copiktra?
The opportunity was concentrated in relapsed or refractory CLL/SLL and follicular lymphoma after at least two prior systemic therapies. It was materially smaller than the markets for front-line BTK inhibitors or broad-use BCL2 therapies.
Can a generic company launch duvelisib before all patents expire?
Potentially, through a successful Paragraph IV challenge, a settlement with an authorized launch date or a skinny-label strategy. Orphan exclusivity and the scope of the generic label would also affect timing.
Why did duvelisib underperform newer CLL therapies?
Duvelisib required use in heavily pretreated patients and carried serious immune-mediated and infectious risks. Newer agents achieved stronger treatment positioning through earlier-line indications, improved sequencing and, in some cases, fixed-duration treatment.
Is duvelisib commercially attractive for licensing?
Its licensing value is limited but not necessarily zero. A buyer would focus on remaining geographic rights, patent duration, regulatory status, API economics, specialty-channel demand and the cost of maintaining pharmacovigilance and medical support.
References
- U.S. Food and Drug Administration. (2018a). FDA approves duvelisib for chronic lymphocytic leukemia and small lymphocytic lymphoma. https://www.fda.gov
- U.S. Food and Drug Administration. (2018b). Copiktra (duvelisib) prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2022). FDA alerts patients and health care professionals about safety concerns with Ukoniq (umbralisib). https://www.fda.gov
- U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov
- U.S. Food and Drug Administration. (n.d.-b). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
- Verastem Oncology. (2019). Verastem Oncology enters into agreement with Secura Bio for COPIKTRA (duvelisib). Company press release.
- Verastem Oncology. (2019-2022). Form 10-K annual reports. U.S. Securities and Exchange Commission. https://www.sec.gov
- U.S. Patent and Trademark Office. (n.d.). Patent Center and patent full-text databases. https://patents.google.com
